1442431-05-1

Basic information

• Product Name: 3-bromo-5-(1-methylcyclopropyl)benzoic acid
• Synonyms: 3-bromo-5-(1-methylcyclopropyl)benzoic acid
• CAS NO: 1442431-05-1
• Molecular Weight: 255.111
• Mol File: 1442431-05-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 3-bromo-5-(1-methylcyclopropyl)benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-bromo-5-(1-methylcyclopropyl)benzoic acid(1442431-05-1)
• EPA Substance Registry System: 3-bromo-5-(1-methylcyclopropyl)benzoic acid(1442431-05-1)

Safety Data

• Hazardous Substances Data: 1442431-05-1(Hazardous Substances Data)

Upstream product

• 1150263-32-3 methyl 3-bromo-5-(prop-1-en-2-yl)benzoate 
• 188813-07-2 methyl 3-bromo-5-iodobenzoate 
• 1442431-04-0 methyl 3-bromo-5-(1-methylcyclopropyl)benzoate 

Downstream Products

• 1442431-07-3 N-(tert-butyl)-N-methyl-3-(1-methylcyclopropyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide 
• 1442431-06-2 3-bromo-N-(tert-butyl)-N-methyl-5-(1-methylcyclopropyl)benzamide 

Relevant articles and documents

CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED NITROGEN-CONTAINING 5-MEMBERED HETEROCYCLES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR GAMMA

The invention provides modulators for the orphan nuclear receptor RORy and methods for treating RORy mediated diseases by administering these novel RORy modulators to a human or a mammal in need thereof. Specifically, the present invention provides carboxamide containing cyclic compounds of Formula (1) to Formula (5) and the enantiomers, diastereomers, tautomers, /V-oxides, solvates and pharmaceutically acceptable salts thereof.

CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED THIAZOLES AND RELATED DERIVATIVES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR[GAMMA]

The invention provides modulators for the orphan nuclear receptor RORy and methods for treating RORy mediated diseases by administering these novel RORy modulators to a human or a mammal in need thereof. Specifically, the present invention provides carboxamide or sulfonamide containing cyclic compounds of Formula (1), (1'), (100), (100'), (200) and (200') and the enantiomers, diastereomers, tautomers, /V-oxides, solvates and pharmaceutically acceptable salts thereof.